Biosynex, a biopharmaceutical company, agreed to acquire a 75% stake in BHR Pharmaceuticals, a provider of Point Of Care diagnostics. Financial terms were not disclosed. "We are very pleased with this acquisition alongside of the founders in BHR, which symbolizes the first majority strategic acquisition in the international development of BIOSYNEX in a major market in which the Point of Care segment is already well established developed. This stake represents a first step in the acquisition strategy pursued actively by Biosynex on 3 axes: complete its product offer, acquire technologies and access international distribution networks," Larry Abensur, Biosynex CEO.